Brief: Novonesis Narrows FY Outlook

Novozymes A/S

06/11/2025 07:00

Nov 6 (Reuters) - Novozymes A/S NSISb.CO:

OUTLOOK FY ORGANIC GROWTH 7-8%

OUTLOOK FY ADJUSTED EBITDA MARGIN 37-38%

ORGANIC SALES GROWTH IS NOW EXPECTED BETWEEN 7-8% (PREVIOUSLY 6-8%)

EXCLUDING EXIT FROM CERTAIN COUNTRIES, ORGANIC SALES GROWTH FOR YEAR IS EXPECTED AT 8-9% (PREVIOUSLY 7-9%)

FY ADJUSTED EBITDA MARGIN IS EXPECTED AT LOWER END OF 37-38% RANGE

Q3 NET REVENUE EUR 1,064.9 MILLION VERSUS EUR 1,057 MILLION SEEN IN COMPANY-CONSENSUS

Q3 ORGANIC GROWTH 6% VERSUS 4.5% SEEN IN COMPANY-CONSENSUS

Q3 ADJUSTED EBITDA EUR 395.3 MILLION VERSUS EUR 390.5 MILLION SEEN IN COMPANY-CONSENSUS

Q3 ADJUSTED EBITDA MARGIN 37.1% VERSUS 37.0% SEEN IN IN COMPANY-CONSENSUS

Source text: ID:nGNE55Q40V

Further company coverage: [NSISb.CO]

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))